Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
3
75%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (25.0%)
N/A3 (75.0%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completednot_applicable

Change in Omega 3 Index in Healthy Adults With OmeGo or a Standard Omega-3 Oil Supplement

NCT06802068
completedphase_4

Cod Liver Oil for Covid-19 Prevention Study

NCT04609423
terminatednot_applicable

Marine Oils and Arthritis

NCT00805116
completednot_applicable

Treating Oxidative Stress and the Metabolic Pathology of Autism

NCT00572741

Clinical Trials (4)

Showing 4 of 4 trials
NCT06802068Not Applicable

Change in Omega 3 Index in Healthy Adults With OmeGo or a Standard Omega-3 Oil Supplement

Completed
NCT04609423Phase 4

Cod Liver Oil for Covid-19 Prevention Study

Completed
NCT00805116Not Applicable

Marine Oils and Arthritis

Terminated
NCT00572741Not Applicable

Treating Oxidative Stress and the Metabolic Pathology of Autism

Completed

All 4 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
4